Physician profile
George Fox
NPI 1568412393
$2,899.87
in general payments reported to CMS, 2019-2025
28 companies · $823 in 2025
The $823 reported for 2025 was more than what 89% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $209 · 2021: $340 · 2022: $379 · 2023: $481 · 2024: $430 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.89 | 2019-2025 | |
| Astellas Pharma US INC | $490.17 | 2022-2025 | Veozah |
| Organon LLC | $295.02 | 2021-2025 | Nexplanon, Jada System |
| Sage Therapeutics, LLC | $242.21 | 2024-2025 | Zurzuvae |
| Channel Medsystems, INC. | $173.52 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $114.46 | 2025 | Myfembree |
| Therapeuticsmd, INC. | $112.12 | 2020-2022 | |
| Shield Therapeutics INC | $108.41 | 2023-2024 | Accrufer |
| Mayne Pharma Commercial LLC | $103.68 | 2021-2025 | |
| Millicent US INC | $86.13 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $82.60 | 2024-2025 | Slynd |
| Coopersurgical, INC. | $80.94 | 2019-2024 | Paragard T 380a |
| Roche Diagnostics Corporation | $59.94 | 2019-2020 | |
| Daiichi Sankyo INC. | $57.57 | 2019-2022 | |
| Allergan, INC. | $51.60 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $48.87 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $46.50 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.26 | 2019-2025 | |
| Medtronic, INC. | $30.79 | 2021-2023 | Truclear |
| Novo Nordisk INC | $19.57 | 2024 | Wegovy, Saxenda |
| Pfizer INC. | $18.50 | 2023 | |
| Cepheid | $17.82 | 2025 | Genexpert |
| Scynexis, INC. | $17.42 | 2022 | |
| Lilly USA, LLC | $15.10 | 2025 | Zepbound, Mounjaro |
| Aspira Women'S Health INC | $14.42 | 2020 | |
| Evofem Biosciences, INC. | $13.60 | 2021 | |
| Merck Sharp & Dohme LLC | $13.58 | 2019 | |
| Boston Scientific Corporation | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.